171 related articles for article (PubMed ID: 19667274)
1. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.
Jang RW; Le Maître A; Ding K; Winton T; Bezjak A; Seymour L; Shepherd FA; Leighl NB
J Clin Oncol; 2009 Sep; 27(26):4268-73. PubMed ID: 19667274
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
Bezjak A; Lee CW; Ding K; Brundage M; Winton T; Graham B; Whitehead M; Johnson DH; Livingston RB; Seymour L; Shepherd FA
J Clin Oncol; 2008 Nov; 26(31):5052-9. PubMed ID: 18809617
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Ng R; Hasan B; Mittmann N; Florescu M; Shepherd FA; Ding K; Butts CA; Cormier Y; Darling G; Goss GD; Inculet R; Seymour L; Winton TL; Evans WK; Leighl NB; ; ;
J Clin Oncol; 2007 Jun; 25(16):2256-61. PubMed ID: 17538170
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
[TBL] [Abstract][Full Text] [Related]
5. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
Winton T; Livingston R; Johnson D; Rigas J; Johnston M; Butts C; Cormier Y; Goss G; Inculet R; Vallieres E; Fry W; Bethune D; Ayoub J; Ding K; Seymour L; Graham B; Tsao MS; Gandara D; Kesler K; Demmy T; Shepherd F; ;
N Engl J Med; 2005 Jun; 352(25):2589-97. PubMed ID: 15972865
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Douillard JY; Rosell R; De Lena M; Carpagnano F; Ramlau R; Gonzáles-Larriba JL; Grodzki T; Pereira JR; Le Groumellec A; Lorusso V; Clary C; Torres AJ; Dahabreh J; Souquet PJ; Astudillo J; Fournel P; Artal-Cortes A; Jassem J; Koubkova L; His P; Riggi M; Hurteloup P
Lancet Oncol; 2006 Sep; 7(9):719-27. PubMed ID: 16945766
[TBL] [Abstract][Full Text] [Related]
7. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
8. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
Alam N; Shepherd FA; Winton T; Graham B; Johnson D; Livingston R; Rigas J; Whitehead M; Ding K; Seymour L
Lung Cancer; 2005 Mar; 47(3):385-94. PubMed ID: 15713522
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Zhu CQ; Ding K; Strumpf D; Weir BA; Meyerson M; Pennell N; Thomas RK; Naoki K; Ladd-Acosta C; Liu N; Pintilie M; Der S; Seymour L; Jurisica I; Shepherd FA; Tsao MS
J Clin Oncol; 2010 Oct; 28(29):4417-24. PubMed ID: 20823422
[TBL] [Abstract][Full Text] [Related]
11. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
Sève P; Lai R; Ding K; Winton T; Butts C; Mackey J; Dumontet C; Dabbagh L; Aviel-Ronen S; Seymour L; Whitehead M; Tsao MS; Shepherd FA; Reiman T
Clin Cancer Res; 2007 Feb; 13(3):994-9. PubMed ID: 17289895
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
13. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
14. Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.
Cortes J; Pérez-García J; Whiting S; Wan Y; Solem C; Tai MH; Margunato-Debay S; Ko A; Fandi A; Botteman M
Clin Breast Cancer; 2018 Oct; 18(5):e919-e926. PubMed ID: 29703690
[TBL] [Abstract][Full Text] [Related]
15. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
16. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
Radice D; Redaelli A
Pharmacoeconomics; 2005; 23(1):69-75. PubMed ID: 15693729
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt W; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Zuna I; Griesinger F; Thomas M;
Ann Oncol; 2013 Apr; 24(4):986-92. PubMed ID: 23161898
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Butts CA; Ding K; Seymour L; Twumasi-Ankrah P; Graham B; Gandara D; Johnson DH; Kesler KA; Green M; Vincent M; Cormier Y; Goss G; Findlay B; Johnston M; Tsao MS; Shepherd FA
J Clin Oncol; 2010 Jan; 28(1):29-34. PubMed ID: 19933915
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.
Couillard-Montminy V; Gagnon PY; Fortin S; Côté J
J Oncol Pharm Pract; 2019 Jan; 25(1):44-51. PubMed ID: 28825377
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
